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for sensitivity analyses showed cost-savings ranging from € 22,525 to € 996,384 of 
prophylaxis with aPCC vs. on-demand with rFVIIa. ConClusions: Three times/
week aPCC prophylaxis could reduce 16% the total treatment cost of severe HA 
with inhibitor, saving up to € 98,000/patient/year.
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objeCtives: While previous studies have shown that overweight and obesity are 
associated with higher costs, less is known about health care costs by place of 
service (POS) at various levels of BMI. This study measures the impact of BMI as a 
continuous variable on health care cost at different places of service. POS categories 
include: pharmacy, doctor’s office, inpatient hospital, outpatient hospital or clinic, 
emergency department, laboratory, and other. Methods: Using 2003-2012 retro-
spective data from large employers throughout the United States, employees’ BMI 
values were calculated using health risk appraisal data. All study employees were 
> = 18, had > = 12 months of health plan coverage after their index BMI screening 
date, and had no medical claims indicating pregnancy. Employees with BMI< 18 (1st 
percentile) or BMI> 47 (99thpercentile) were excluded. Generalized additive models 
on 12-month post-index POS costs produced estimates of the nonlinear relation-
ship between BMI and cost after controlling for age, gender, marital status, race, 
salary, zip-code region and index year. Results: This study included 71,633 eligible 
employees; 32.0% were female. The average BMI, age and annual salary were 27.3, 
39.8 years and $81,382, respectively. Costs increased significantly with BMI in each 
POS (P< 0.001). Total adjusted annual per-employee health care cost estimates at BMI 
values of 25, 30, 35, and 45 were $3043, $3932, $4357, and $7248, respectively. Cost 
estimates by POS at these BMI values were: Pharmacy ($706, $903, $1106, $1372), 
Inpatient ($398, $678, $643, $2440), Outpatient ($799, $1057, $1113, $1516), Office 
($939, $1044, $1174, $1495), Emergency ($131, $159, $200, $186), Laboratory ($34, $38, 
$46, $43), and Other ($35, $53, $74, $196), respectively. ConClusions: Employees 
with higher BMI levels incurred more cost at each of the 7 places of service. Because 
of the high prevalence of overweight and obesity, these costs represent a significant 
burden for US employers.
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objeCtives: This study determines the distribution of health care costs by place 
of service (POS; pharmacy, doctor’s office, inpatient hospital, outpatient hospital 
or clinic, emergency department, laboratory, and other) among employees based 
upon body mass index (BMI). Methods: Using 2003-2012 retrospective data from 
large employers throughout the US, employees’ BMIs from health risk appraisal data 
defined three main cohorts (BMI< 27 [normal weight], 27< = BMI< 30 [overweight] and 
BMI> = 30 [obese]). The 27< = BMI< 30 cohort was further divided into 3 comorbidity 
subcohorts: those without diabetes, hypertension or dyslipidemia (NonT2DHtnDys), 
those with hypertension or dyslipidemia without diabetes (HtnDys), and those with 
diabetes with or without hypertension or dyslipidemia (T2D). All eligible employees 
were aged> = 18, had > = 12 months post-index health plan coverage, and had no 
pregnancy claims. Annual post-index costs were compared between cohorts and 
between subcohorts using two-part regression modeling, controlling for age, gender, 
marital status, race, salary, region, and index year. Results: This study included 
39,696 (BMI< 27), 14,281 (27< = BMI< 30), and 18,801 (BMI> = 30) eligible employees, 
with total adjusted health care costs of $3,191, $3,695, and $4,844, respectively. 
Employees with higher BMI were significantly more likely to incur health care costs 
in every POS category. Obese employees (BMI> = 30) had particularly high inpatient 
costs compared to other cohorts, averaging twice the cost of the BMI< 27 cohort 
($919 vs. $431, P< 0.05). Total costs among subcohorts of 27< = BMI< 30 were $2,863 
(NonT2DHtnDys), $5,271 (HtnDys), and $7,594 (T2D). NonT2DHynDys employees had 
significantly lower health care cost than other subcohorts in every POS category. 
The T2D subcohort had significantly higher pharmacy, inpatient, doctor’s office, 
laboratory and other health care costs when compared to HtnDys. ConClusions: 
Employees with higher BMI incurred higher average health care costs than other 
employees at all places of service. Comorbidities, particularly diabetes, exacerbate 
health care costs of overweight employees. This represents a significant economic 
burden for US employers given the high prevalence of overweight and obesity.
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objeCtives: Hemophilia A is rare bleeding disorder where patients have defective 
or deficient levels of coagulation factor VIII (FVIII). Recombinant FVIIII (rFVIII) are 
manufactured to treat the patients, either as a full-length rFVIII (FL-rFVIII) mol-
ecule replicating natural human FVIII or with the B-domain deleted (BDD-rFVIII). It 
has been suggested that Deletion of B domain had been implemented to improve 
production profitability. However, this deletion has been shown to induce increase 
factor consumption by 32.8% in the US (Epstein 2011) and also may increase the 
risk of developing inhibitors for previously treated patients (PTP) Hazard Ratio= 10.8 
(Aledort 2011). Both differences can have an important impact on patient health 
and on the national health care budget. Methods: A Excel-based decision tree 
model had been developed to compare the overall cost to treat severe haemophilia 
A patients from a health care system perspective with the most used FL-rFVIII and 
objeCtives: To assess the cost-effectiveness of ferric carboxymaltose (FCM) and 
iron sucrose (IS) in the correction of iron-deficiency anaemia (IDA) before elec-
tive major surgery in non-cardiac surgical patients and predict potential budget 
expenses for the day care services and blood transfusions. Methods: The pharma-
coeconomic model was developed based on the data from multicentre prospective 
study (E. Bisbe et al., 2011) on the efficacy of FCM and IS for correcting preopera-
tive anaemia in patients undergoing major elective non-cardiac surgery. The cost-
effectiveness of two intravenous iron formulations was measured as total costs of 
medicines and day care services per one patient attained iron replenishment or per 
one patient without IDA at the end of treatment. Budget impact analysis included 
expenses for the day care services and blood transfusion procedures during intraop-
erative and/or postoperative period. Sensitivity analysis was performed by including 
in the model of iron sucrose similars (ISSs). It was considered that treatment with 
ISSs requires dose increase up to 120-135% of dose of the original IS (E. Lee et al., 
2013; J. Rottermbourg et al., 2010). Results: The clinical efficacy of FCM was higher 
compared to that of IS, this was also reflected in better pharmacoeconomic profile 
of FCM. The CERs were 14,473.61 RUB and 15,222.83 RUB per one patient attained 
iron replenishment in the FCM and IS groups, respectively. Treatment with FCM was 
associated with 2.5-fold lower costs of day care services and 2.7-fold lower expenses 
for blood transfusion procedures. Additional expenses for the day care services were 
required for patients received ISSs due to increased frequency of injections; this was 
resulted in the highest CERs in the ISS group. ConClusions: The present study 
has demonstrated that administration of FCM is economically effective strategy to 
replenish body iron stores and correct IDA in surgical patients.
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objeCtives: Although there are several hemostats available, drawbacks include 
limitations with efficacy on first attempt and sub-optimal ease-of-use. Literature 
suggests that more efficacious hemostats may avert hospital resources and offset 
upfront acquisition costs. A study was conducted to estimate the cost impact of a 
novel fibrin sealant patch (i.e., EVARREST™) versus standard of care (SoC) in mild-
moderate and problematic soft tissue surgical bleeding. Methods: An economic 
model was developed to quantify 30-day cost impact of EVARREST from a U.S. hospi-
tal perspective. Key resources, collected from two trials, included quantity of initial 
treatment and re-treatment, operating time, hospitalization, transfusion risk, amount 
transfused, and ventilator utilization. SoC was composed of Surgicel (mild-moderate 
bleeding) or Surgicel (88%) and conventional methods (12%) (problematic bleeding). 
The primary analysis included resources clinically related to the significant hemo-
stasis benefit of EVARREST vs. control (i.e., initial and re-treatment, operating time 
and transfusion). A secondary analysis included all resources collected. Published 
data on U.S. costs were applied to resource use. Results: In problematic bleeding, 
the primary analysis predicted that EVARREST is cost-savings for the hospital vs. 
SoC (-$462 USD per patient) with robust one-way sensitivity results (range: -$199 
to -$6,212 USD). In mild-moderate bleeding, EVARREST acquisition cost is partially 
offset with a cost impact of $507 USD per patient (sensitivity range: $175 to $851 USD). 
Secondary analyses predicted further resource reduction with EVARREST leading 
to cost-savings (-$5,096 USD per patient) or reduction in cost impact ($233 USD per 
patient) for problematic and mild-moderate bleeding respectively. ConClusions: 
This analysis suggests that the hospital cost impact of EVARREST depends on type 
of bleed. In problematic soft tissue bleeding, EVARREST may result in important cost 
savings for hospitals, in addition to meeting an important unmet need. Further study 
in additional populations may be required to confirm findings.
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objeCtives: To estimate the treatment cost of prophylaxis and acute break-
through bleeds with Activated Prothrombin Complex Concentrate (aPCC) versus 
on-demand therapy with recombinant Factor VIIa (rFVIIa) for severe hemophilia 
A (HA) with inhibitor patients, from the Spanish Healthcare System perspec-
tive. Methods: A cost-analysis model was used to compare annual cost per 
patient of aPCC prophylaxis versus rFVIIa on-demand treatment. Cost estimation 
included prophylaxis pharmaceutical costs (aPCC), on-demand pharmaceutical 
treatment for bleedings, bleeding events management (excluding factor), surgeries 
and HA management. Prophylaxis regimen was 75.72IU/kg three times per week. 
Total dosage for each hemorrhagic event was 673.46µg/kg for rFVIIa and 233.13U/
kg for aPCC, annual number of bleedings was 25 for on-demand therapy and 8 
for prophylaxis, assuming 69% reduction due to prophylaxis. A baseline bleed-
ing management cost (€ 2,971) was estimated based on resource use provided 
by an expert panel for four bleeding sites (joints [62.5%], muscle and soft tissue 
[28.6%], mucous membranes [3.6%] and other sites [5.4%]). Drug (ex-factory price 
with mandatory 7.5% rebate) and unitary costs (€ , 2013) were obtained from local 
databases. Results: Estimated annual treatment cost of prophylaxis with aPCC 
(€ 523,473) was lower than on-demand treatment with rFVIIa (€ 622,183). Based 
on the total agent consumption (789,109IU [aPCC] and 1,050,067µg [rFVIIa]) the 
pharmaceutical cost accounted for € 496,350 for aPCC (14.6% on-demand bleed-
ings and 85.4% prophylaxis) compared to € 543,866 for rFVIIa (average bleeding 
cost of € 9,062 [aPCC] and € 21,556 [rFVIIa]). Yearly bleedings cost was € 23,770 for 
aPCC versus € 74,963 for rFVIIa. A baseline cost for HA management (€ 2,645) and 
an average cost of surgeries (€ 708/year) were estimated for both strategies. Results 
